【摘要】心血管疾病(cardiovascular disease,CVD)是慢性肾脏病(chronic kidney disease,CKD)患者常见的并发症，也是终末期肾病患者的主要死亡原因。故在CKD 患者中早期识别并干预CVD 是至关重要的。B 型利钠肽(BNP)和N 末端B 型利钠肽原(NT-proBNP)作为心脏生物标志物，已被用来诊断心力衰竭和评估病情严重程度与预后。但对于CKD患者来说，CKD本身与透析治疗等因素往往会影响BNP、NTproBNP水平，使其在CKD 患者中诊断心力衰竭和评估病情严重程度与预后方面面临挑战。本综述通过对BNP 和NTproBNP 概况回顾，分析了CKD 患者血清BNP 和NT-proBNP 的水平及影响因素，并对BNP 和NTproBNP在CKD中的应用前景作一综述。
[1] Pei M, Aguiar R, Pagels AA, et al.Health-related quality of life as predictor of mortality in end-stage renal disease patients: an observational study. BMC Nephrol. 2019 Apr 29;20(1):144.
[2] Chapter 8: Cardiovascular disease in patients with ESRD. Am J Kidney Dis. 2019;73(3, Supplement 1):S501–S18.
[3] Fu S, Ping P, Wang F,et al. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. J Biol Eng. 2018 Jan 12;12:2.
[4] Harrison TG, Shukalek CB, Hemmelgarn BR, et al. Association of NT-proBNP and BNP With Future Clinical Outcomes in Patients With ESKD: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2020 Aug;76(2):233-247.
[5] Maisel AS, Duran JM, Wettersten N. Natriuretic Peptides in Heart Failure: Atrial and B-type Natriuretic Peptides. Heart Fail Clin. 2018 Jan;14(1):13-25.
[6] Nakagawa Y, Nishikimi T, Kuwahara K. Atrial and brain natriuretic peptides: Hormones secreted from the heart. Peptides. 2019 Jan;111:18-25. .
[7] Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail. 2017 Aug;23(8):628-651.
[8] Fu S, Ping P, Zhu Q, et al. Brain Natriuretic Peptide and Its Biochemical, Analytical, and Clinical Issues in Heart Failure: A Narrative Review. Front Physiol. 2018 Jun 5;9:692.
[9] Kato Y, Mori K, Kasahara M, et al. Natriuretic peptide receptor guanylyl cyclase-A pathway counteracts glomerular injury evoked by aldosterone through p38 mitogen-activated protein kinase inhibition. Sci Rep. 2017 Apr 21;7:46624.
[10] Staffel J, Valletta D, Federlein A, et al. Natriuretic Peptide Receptor Guanylyl Cyclase-A in Podocytes is Renoprotective but Dispensable for Physiologic Renal Function. J Am Soc Nephrol. 2017 Jan;28(1):260-277.
[11] Guo Q, Wang J, Ge Y, et al. Brain natriuretic peptide mitigates TIMP2 induction and reinstates extracellular matrix catabolic activity via GSK3β inhibition in glomerular podocytes exposed to a profibrogenic milieu. Am J Transl Res. 2019 Feb 15;11(2):964-973.
[12] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会,等.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
[13] Stokes NR, Dietz BW, Liang JJ. Cardiopulmonary laboratory biomarkers in the evaluation of acute dyspnea.Open Access Emerg Med. 2016 May 17;8:35-45.
[14] Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013 Jul 27;382(9889):339-52.
[15] Roberts MA, Hare DL, Sikaris K, et al. Temporal trajectory of B-type natriuretic peptide in patients with CKD stages 3 and 4, dialysis, and kidney transplant. Clin J Am Soc Nephrol. 2014 Jun 6;9(6):1024-32.
[16] Schaub JA, Coca SG, Moledina DG,et al. Amino-Terminal Pro-B-Type Natriuretic Peptide for Diagnosis and Prognosis in Patients With Renal Dysfunction: A Systematic Review and Meta-Analysis. JACC Heart Fail. 2015 Dec;3(12):977-89.
[17] Snaedal S, Qureshi AR, Carrero JJ, et al. Determinants of N-terminal pro-brain natriuretic peptide variation in hemodialysis patients and prediction of survival. Blood Purif. 2014;37(2):138-45.
[18] Scholz SS, Vukadinovi? D, Lauder L, et al. Effects of Arteriovenous Fistula on Blood Pressure in Patients With End-Stage Renal Disease: A Systematic Meta-Analysis. J Am Heart Assoc. 2019 Feb 19;8(4):e011183.
[19] Rao NN, Stokes MB, Rajwani A,et al. Effects of Arteriovenous Fistula Ligation on Cardiac Structure and Function in Kidney Transplant Recipients. Circulation. 2019 Jun 18;139(25):2809-2818.
[20] Laveborn E, Lindmark K, Skagerlind M, et al. NT-proBNP and troponin T levels differ after haemodialysis with a low versus high flux membrane. Int J Artif Organs. 2015 Feb;38(2):69-75.
[21] Koz S, Sahin I, Temel I, et al. Elimination of NTproBNP in peritoneal dialysis patients. Does peritoneal membrane type make a difference in plasma level and elimination of NTproBNP? Clin Nephrol. 2016 May;85(5):266-72.
[22] Kawai Y, Tanaka S, Yoshida H, et al. Association of B-Type Natriuretic Peptide Level With Residual Kidney Function in Incident Peritoneal Dialysis Patients. Perit Dial Int. 2019 Mar-Apr;39(2):147-154.
[23] Fahim MA, Hayen A, Horvath AR, et al. N-terminal pro-B-type natriuretic peptide variability in stable dialysis patients. Clin J Am Soc Nephrol. 2015 Apr 7;10(4):620-9.
[24] Touzot M, Seris P, Maheas C, et al. Mathematical model to predict B-type natriuretic peptide levels in haemodialysis patients. Nephrology (Carlton). 2020 Jan;25(1):82-89.
[25] Ducros J, Larifla L, Merault H, et al. N-terminal Pro-B-Type Natriuretic Peptide and Malnutrition in Patients on Hemodialysis. Int J Nephrol. 2020 Mar 5;2020:9528014.
[26] Di Marca S, Rando A, Cataudella E, et al. B-type natriuretic peptide may predict prognosis in older adults admitted with a diagnosis other than heart failure. Nutr Metab Cardiovasc Dis. 2018 Jun;28(6):636-642.
[27] Hayashi T, Yasuda K, Kimura T, et al. Prognostic Significance of Asymptomatic Brain Natriuretic Peptide Elevation at Nephrology Referral in Patients with Chronic Kidney Disease. Am J Nephrol. 2018;48(3):205-213.
[28] Niizuma S, Iwanaga Y, Washio T, et al. Clinical Significance of Increased Cardiac Troponin T in Patients with Chronic Hemodialysis and Cardiovascular Disease: Comparison to B-Type Natriuretic Peptide and A-Type Natriuretic Peptide Increase. Kidney Blood Press Res. 2019;44(5):1050-1062.
[29] Gromadziński L, Januszko-Giergielewicz B, Czarnacka K, et al. NT-proBNP in the Prognosis of Death or Need for Renal Replacement Therapy in Patients with Stage 3-5 Chronic Kidney Disease. Cardiorenal Med. 2019;9(2):125-134.
[30] Untersteller K, Girerd N, Duarte K, et al. NT-proBNP and Echocardiographic Parameters for Prediction of Cardiovascular Outcomes in Patients with CKD Stages G2-G4. Clin J Am Soc Nephrol. 2016 Nov 7;11(11):1978-1988.
[31] Voroneanu L, Siriopol D, Nistor I, et al. Superior predictive value for NTproBNP compared with high sensitivity cTnT in dialysis patients: a pilot prospective observational study. Kidney Blood Press Res. 2014;39(6):636-47.
[32] Oh HJ, Lee MJ, Kwon YE, et al. Which Biomarker is the Best for Predicting Mortality in Incident Peritoneal Dialysis Patients: NT-ProBNP, Cardiac TnT, or hsCRP?: A Prospective Observational Study. Medicine (Baltimore). 2015 Nov;94(44):e1636.
[33] Niizuma S, Iwanaga Y, Yahata T, et al. Renocardiovascular Biomarkers: from the Perspective of Managing Chronic Kidney Disease and Cardiovascular Disease. Front Cardiovasc Med. 2017 Mar 6;4:10.
[34] Stenberg J, Melin J, Lindberg M,et al. Brain natriuretic peptide reflects individual variation in hydration status in hemodialysis patients. Hemodial Int. 2019 Jul;23(3):402-413.
[35] Chazot C, Rozes M, Vo-Van C, et al. Brain Natriuretic Peptide Is a Marker of Fluid Overload in Incident Hemodialysis Patients. Cardiorenal Med. 2017 Jun;7(3):218-226.
[36] Schwermer K, Hoppe K, Radziszewska D, et al. N?terminal pro?B-type natriuretic peptide as a marker of hypervolemia and predictor of increased mortality in patients on hemodialysis. Pol Arch Med Wewn. 2015;125(7-8):560-9.
[37] Alexandrou ME, Balafa O, Sarafidis P. Assessment of Hydration Status in Peritoneal Dialysis Patients: Validity, Prognostic Value, Strengths, and Limitations of Available Techniques. Am J Nephrol. 2020;51(8):589-612.
